HALO
Income statement / Annual
Last year (2024), Halozyme Therapeutics, Inc.'s total revenue was $1.02 B,
an increase of 22.44% from the previous year.
In 2024, Halozyme Therapeutics, Inc.'s net income was $444.09 M.
See Halozyme Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$1.02 B |
$829.25 M |
$660.12 M |
$443.31 M |
$267.59 M |
$195.99 M |
$151.86 M |
$316.61 M |
$146.69 M |
$135.06 M |
| Cost of Revenue |
$159.42 M
|
$192.36 M
|
$139.30 M
|
$81.41 M
|
$43.37 M
|
$45.55 M
|
$10.14 M
|
$31.15 M
|
$33.21 M
|
$29.25 M
|
| Gross Profit |
$855.91 M
|
$636.89 M
|
$520.81 M
|
$361.90 M
|
$224.23 M
|
$150.45 M
|
$141.73 M
|
$285.46 M
|
$113.49 M
|
$105.81 M
|
| Gross Profit Ratio |
0.84
|
0.77
|
0.79
|
0.82
|
0.84
|
0.77
|
0.93
|
0.9
|
0.77
|
0.78
|
| Research and Development Expenses |
$79.05 M
|
$76.36 M
|
$66.61 M
|
$35.67 M
|
$34.24 M
|
$140.80 M
|
$150.25 M
|
$150.64 M
|
$150.84 M
|
$93.24 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$60.80 M
|
$53.82 M
|
$45.85 M
|
$40.03 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$154.34 M
|
$149.18 M
|
$143.53 M
|
$50.32 M
|
$45.74 M
|
$77.25 M
|
$60.80 M
|
$53.82 M
|
$45.85 M
|
$40.03 M
|
| Other Expenses |
$71.05 M
|
$73.77 M
|
$43.15 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$304.43 M
|
$299.32 M
|
$253.28 M
|
$86.00 M
|
$79.97 M
|
$218.06 M
|
$211.06 M
|
$204.46 M
|
$196.70 M
|
$133.26 M
|
| Cost And Expenses |
$463.85 M
|
$491.68 M
|
$392.59 M
|
$167.41 M
|
$123.34 M
|
$263.60 M
|
$221.19 M
|
$235.61 M
|
$229.90 M
|
$162.51 M
|
| Interest Income |
$0.00
|
$0.00
|
$15.90 M
|
$6.42 M
|
$14.95 M
|
$7.11 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$18.10 M
|
$18.76 M
|
$16.95 M
|
$7.53 M
|
$20.38 M
|
$11.63 M
|
$18.04 M
|
$21.98 M
|
$19.98 M
|
$5.20 M
|
| Depreciation & Amortization |
$81.31 M
|
$84.86 M
|
$49.64 M
|
$3.00 M
|
$3.28 M
|
$4.07 M
|
$2.39 M
|
$2.16 M
|
$2.41 M
|
$1.68 M
|
| EBITDA |
$656.54 M |
$451.95 M |
$315.51 M |
$259.04 M |
$152.96 M |
-$56.56 M |
-$69.33 M |
$83.16 M |
-$79.47 M |
-$25.35 M |
| EBITDA Ratio |
0.65
|
0.55
|
0.47
|
0.62
|
0.54
|
-0.34
|
-0.46
|
0.26
|
-0.57
|
-0.2
|
| Operating Income Ratio |
0.54
|
0.41
|
0.41
|
0.62
|
0.54
|
-0.34
|
-0.46
|
0.26
|
-0.57
|
-0.2
|
| Total Other Income/Expenses Net |
$5.66 M
|
$10.76 M
|
-$18.61 M
|
-$27.38 M
|
-$14.95 M
|
-$4.64 M
|
-$10.46 M
|
-$19.39 M
|
-$18.65 M
|
-$4.78 M
|
| Income Before Tax |
$557.13 M
|
$348.33 M
|
$248.92 M
|
$248.52 M
|
$129.30 M
|
-$72.25 M
|
-$79.79 M
|
$61.61 M
|
-$101.86 M
|
-$32.23 M
|
| Income Before Tax Ratio |
0.55
|
0.42
|
0.38
|
0.56
|
0.48
|
-0.37
|
-0.53
|
0.19
|
-0.69
|
-0.24
|
| Income Tax Expense |
$113.04 M
|
$66.74 M
|
$46.79 M
|
-$154.19 M
|
$217,000.00
|
-$11,000.00
|
$537,000.00
|
-$1.36 M
|
$1.16 M
|
$3.52 M
|
| Net Income |
$444.09 M
|
$281.59 M
|
$202.13 M
|
$402.71 M
|
$129.09 M
|
-$72.24 M
|
-$80.33 M
|
$62.97 M
|
-$103.02 M
|
-$32.23 M
|
| Net Income Ratio |
0.44
|
0.34
|
0.31
|
0.91
|
0.48
|
-0.37
|
-0.53
|
0.2
|
-0.7
|
-0.24
|
| EPS |
3.5 |
2.13 |
1.48 |
2.86 |
0.95 |
-0.5 |
-0.56 |
0.46 |
-0.81 |
-0.25 |
| EPS Diluted |
3.43 |
2.1 |
1.44 |
2.74 |
0.91 |
-0.5 |
-0.56 |
0.45 |
-0.81 |
-0.25 |
| Weighted Average Shares Out |
$126.83 M
|
$131.93 M
|
$136.84 M
|
$140.65 M
|
$136.21 M
|
$144.33 M
|
$143.45 M
|
$136.42 M
|
$127.19 M
|
$126.70 M
|
| Weighted Average Shares Out Diluted |
$129.42 M
|
$134.20 M
|
$140.61 M
|
$146.80 M
|
$141.46 M
|
$144.33 M
|
$143.60 M
|
$139.07 M
|
$127.96 M
|
$126.70 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
